Feng JG et al. further corroborated this potential of ANXA2, alongside Cdc42, as ESCC prognostic biomarkers, in a study that found that downregulation of ANXA2 and upregulated Cdc42 expression significantly correlated with the presence of lymph node metastasis and poor tumor differentiation, both hallmarks of aggressive tumor behavior [60]. Here, ANXA2 is linked to neoplasm.